Format

Send to

Choose Destination
Clin Chim Acta. 2015 Jan 1;438:252-4. doi: 10.1016/j.cca.2014.09.008. Epub 2014 Sep 11.

Evaluation of the performance of a new OptiScanner™ 5000 system for an intermittent glucose monitoring.

Author information

1
Laboratorio di Analisi, Ospedale San Paolo, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milano, Italy. Electronic address: Alessandra.barassi@unimi.it.
2
UO Anestesia e Rianimazione, Polo Universitario San Paolo, Milano, Italy.
3
Laboratorio di Analisi, Ospedale San Paolo, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milano, Italy.
4
Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche, Università di Milano, Milano, Italy.
5
UO Anestesia e Rianimazione, Polo Universitario San Paolo, Milano, Italy; Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milano, Italy.

Abstract

BACKGROUND:

Mid-infrared spectral technology has shown a high degree of promise in detecting glucose in plasma. OptiScan Biomedical has developed a glucose monitor based on mid-infrared spectroscopy that withdraws blood samples and measures plasma glucose. The objective of this study was to evaluate the accuracy and performance of the OptiScanner™ 5000 system on different pools of blood.

METHODS:

This study was performed to validate the blood glucose measurements obtained with the OptiScanner™ 5000 by comparing them to Central Laboratory glucose measurements (VITROS® 5600 Integrated System) as a comparative method across a broad range of glucose values over a three day period to obtain 80-90 paired measurements.

RESULTS:

A total of 81 paired measurements, distributed between 33 and 320mg/100mL of glucose, were performed. The aggregate data points were within International Organization for Standardization standards, with 100% of the glucose values within ±15%.

CONCLUSIONS:

The current study suggests that a mid-IR fixed-wavelength system (OptiScanner) can measure glucose accurately across a wide range of glucose values in plasma of ICU patients.

KEYWORDS:

Intermittent glucose monitoring; mid-IR fixed-wavelength system; new OptiScanner™ 5000 system

PMID:
25218698
DOI:
10.1016/j.cca.2014.09.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center